Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2021 Apr 27:2021.04.26.441518. [Version 1] doi: 10.1101/2021.04.26.441518

Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity

William E Matchett, Vineet Joag, J Michael Stolley, Frances K Shepherd, Clare F Quarnstrom, Clayton K Mickelson, Sathi Wijeyesinghe, Andrew G Soerens, Samuel Becker, Joshua M Thiede, Eyob Weyu, Stephen O’Flanagan, Jennifer A Walter, Michelle N Vu, Vineet D Menachery, Tyler D Bold, Vaiva Vezys, Marc K Jenkins, Ryan A Langlois, David Masopust
PMCID: PMC8095198  PMID: 33948591

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing antibodies target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with HAd5 expressing the nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and k18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral antigens, even if they are not a target of neutralizing antibodies, to broaden epitope coverage and immune effector mechanisms.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES